B cell depletion in HIV-1 subtype A infected Ugandan adults: Relationship to CD4 T cell count, viral load and humoral immune responses

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Oballah, Peter ^a   Flach, Britta ^a,b,c   Eller, Leigh A ^b,c   Eller, Michael A ^b,c   Ouma, Benson ^a   de Souza, Mark ^b,c,d   Kibuuka, Hannah N ^a   Wabwire Mangen, Fred ^a,e   Brown, Bruce K ^b,c   Michael, Nelson L ^b,f   Robb, Merlin L ^b,c   Montefiori, David ^g   Polonis, Victoria R ^b,f  

^a Makerere University   (Uganda)

^b Military HIV Research Program   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^d ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^e MAKERERE UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Uganda)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^g DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY;

ADULT; AFRICA; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE A; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; VIRUS LOAD; VIRUS NEUTRALIZATION; ADOLESCENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; GENETIC RECOMBINATION; GENETICS; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MIDDLE AGED; SERODIAGNOSIS; UGANDA; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, HUMORAL; LYMPHOCYTE DEPLETION; MIDDLE AGED; NEUTRALIZATION TESTS; RECOMBINATION, GENETIC; T-LYMPHOCYTES, HELPER-INDUCER; UGANDA; VIRAL LOAD; YOUNG ADULT;

EID: 80051997273     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022653     Document Type: Article

References (83)

1. Levy JA, (2009) HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 23: 147-160.
2. Yates A, Stark J, Klein N, Antia R, Callard R, (2007) Understanding the slow depletion of memory CD4+ T cells in HIV infection. PLoS Med 4: e177.
3. Shen X, Tomaras GD, Alterations of the B-cell response by HIV-1 replication. Curr HIV/AIDS Rep 8: 23-30.
4. Moir S, Fauci AS, (2009) B cells in HIV infection and disease. Nat Rev Immunol 9: 235-245.
5. Kalia V, Sarkar S, Gourley TS, Rouse BT, Ahmed R, (2006) Differentiation of memory B and T cells. Curr Opin Immunol 18: 255-264.
6. De Milito A, Morch C, Sonnerborg A, Chiodi F, (2001) Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS 15: 957-964.
7. Titanji K, Nilsson A, Morch C, Samuelsson A, Sonnerborg A, et al. (2003) Low frequency of plasma nerve-growth factor detection is associated with death of memory B lymphocytes in HIV-1 infection. Clin Exp Immunol 132: 297-303.
8. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, et al. (1983) Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 309: 453-458.
9. Epeldegui M, Thapa DR, De la Cruz J, Kitchen S, Zack JA, et al. (2010) CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS One 5: e11448.
10. Imbeault M, Ouellet M, Giguere K, Bertin J, Belanger D, et al. (2011) Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment. J Virol 85: 2189-2200.
11. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, et al. (2008) Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 205: 1797-1805.
12. Martinez-Maza O, Crabb E, Mitsuyasu RT, Fahey JL, Giorgi JV, (1987) Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol 138: 3720-3724.
13. Katz IR, Krown SE, Safai B, Oettgen HF, Hoffmann MK, (1986) Antigen-specific and polyclonal B-cell responses in patients with acquired immunodeficiency disease syndrome. Clin Immunol Immunopathol 39: 359-367.
14. Gaidano G, Capello D, Carbone A, (2000) The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis. Semin Oncol 27: 431-441.
15. De Milito A, (2004) B lymphocyte dysfunctions in HIV infection. Curr HIV Res 2: 11-21.
16. Moir S, Buckner CM, Ho J, Wang W, Chen J, et al. (2010) B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 116: 5571-5579.
17. Tangye SG, Avery DT, Deenick EK, Hodgkin PD, (2003) Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. J Immunol 170: 686-694.
18. Chirmule N, Oyaizu N, Kalyanaraman VS, Pahwa S, (1992) Inhibition of normal B-cell function by human immunodeficiency virus envelope glycoprotein, gp120. Blood 79: 1245-1254.
19. Conge AM, Tarte K, Reynes J, Segondy M, Gerfaux J, et al. (1998) Impairment of B-lymphocyte differentiation induced by dual triggering of the B-cell antigen receptor and CD40 in advanced HIV-1-disease. AIDS 12: 1437-1449.
20. Letvin NL, Barouch DH, Montefiori DC, (2002) Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 20: 73-99.
21. Mascola JR, (2003) Defining the protective antibody response for HIV-1. Curr Mol Med 3: 209-216.
22. Richman DD, Wrin T, Little SJ, Petropoulos CJ, (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-4149.
23. Moore JP, Cao Y, Ho DD, Koup RA, (1994) Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 68: 5142-5155.
24. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
25. Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, et al. (2006) Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 80: 6155-6164.
26. Chuenchitra T, Wasi C, Louisirirojchanakul S, Nitayaphan S, Sutthent R, et al. (2003) Longitudinal study of humoral immune responses in HIV type 1 subtype CRF01_AE (E)-infected Thai patients with different rates of disease progression. AIDS Res Hum Retroviruses 19: 293-305.
27. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019-2022.
28. Piantadosi A, Panteleeff D, Blish CA, Baeten JM, Jaoko W, et al. (2009) Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 83: 10269-10274.
29. Forthal DN, Landucci G, Keenan B, (2001) Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res Hum Retroviruses 17: 553-561.
30. Ahmad A, Morisset R, Thomas R, Menezes J, (1994) Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J Acquir Immune Defic Syndr 7: 428-437.
31. Ljunggren K, Broliden PA, Morfeldt-Manson L, Jondal M, Wahren B, (1988) IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin Exp Immunol 73: 343-347.
32. Sawyer LA, Katzenstein DA, Hendry RM, Boone EJ, Vujcic LK, et al. (1990) Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res Hum Retroviruses 6: 341-356.
33. Rook AH, Lane HC, Folks T, McCoy S, Alter H, et al. (1987) Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J Immunol 138: 1064-1067.
34. Ahmad R, Sindhu ST, Toma E, Morisset R, Vincelette J, et al. (2001) Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 21: 227-233.
35. Tyler DS, Stanley SD, Nastala CA, Austin AA, Bartlett JA, et al. (1990) Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 144: 3375-3384.
36. Banks ND, Kinsey N, Clements J, Hildreth JE, (2002) Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 18: 1197-1205.
37. Gomez-Roman VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, et al. (2005) Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 174: 2185-2189.
38. Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, et al. (2006) Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 177: 4028-4036.
39. Klasse PJ, Sattentau QJ, (2002) Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 83: 2091-2108.
40. Guwatudde D, Wabwire-Mangen F, Eller LA, Eller M, McCutchan F, et al. (2009) Relatively low HIV infection rates in rural Uganda, but with high potential for a rise: a cohort study in Kayunga District, Uganda. PLoS One 4: e4145.
41. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM, (2008) The challenge of HIV-1 subtype diversity. N Engl J Med 358: 1590-1602.
42. Arroyo MA, Sateren WB, Serwadda D, Gray RH, Wawer MJ, et al. (2006) Higher HIV-1 incidence and genetic complexity along main roads in Rakai District, Uganda. J Acquir Immune Defic Syndr 43: 440-445.
43. Hoelscher M, Dowling WE, Sanders-Buell E, Carr JK, Harris ME, et al. (2002) Detection of HIV-1 subtypes, recombinants, and dual infections in east Africa by a multi-region hybridization assay. AIDS 16: 2055-2064.
44. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864.
45. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
46. Montefiori DC, (2005) Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter 12: Unit 12 11.
47. Cox JH, (1999) HIV-1-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC). Methods Mol Med 17: 373-381.
48. Brown BK, Wieczorek L, Sanders-Buell E, Rosa Borges A, Robb ML, et al. (2008) Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375: 529-538.
49. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, et al. (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84: 1439-1452.
50. Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, et al. (2005) Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23: 2522-2529.
51. Titanji K, Chiodi F, Bellocco R, Schepis D, Osorio L, et al. (2005) Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 19: 1947-1955.
52. Titanji K, De Milito A, Cagigi A, Thorstensson R, Grutzmeier S, et al. (2006) Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 108: 1580-1587.
53. Chong Y, Ikematsu H, Yamamoto M, Murata M, Yamaji K, et al. (2004) Increased frequency of CD27- (naive) B cells and their phenotypic alteration in HIV type 1-infected patients. AIDS Res Hum Retroviruses 20: 621-629.
54. Chong Y, Ikematsu H, Kikuchi K, Yamamoto M, Murata M, et al. (2004) Selective CD27+ (memory) B cell reduction and characteristic B cell alteration in drug-naive and HAART-treated HIV type 1-infected patients. AIDS Res Hum Retroviruses 20: 219-226.
55. De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, et al. (2004) Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 103: 2180-2186.
56. D'Orsogna LJ, Krueger RG, McKinnon EJ, French MA, (2007) Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. AIDS 21: 1747-1752.
57. Hart M, Steel A, Clark SA, Moyle G, Nelson M, et al. (2007) Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol 178: 8212-8220.
58. Morrow M, Valentin A, Little R, Yarchoan R, Pavlakis GN, (2008) A splenic marginal zone-like peripheral blood CD27+B220- B cell population is preferentially depleted in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 24: 621-633.
59. Nagase H, Agematsu K, Kitano K, Takamoto M, Okubo Y, et al. (2001) Mechanism of hypergammaglobulinemia by HIV infection: circulating memory B-cell reduction with plasmacytosis. Clin Immunol 100: 250-259.
60. Widney D, Gundapp G, Said JW, van der Meijden M, Bonavida B, et al. (1999) Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 93: 114-123.
61. Kuhrt D, Faith SA, Leone A, Rohankedkar M, Sodora DL, et al. (2010) Evidence of early B-cell dysregulation in simian immunodeficiency virus infection: rapid depletion of naive and memory B-cell subsets with delayed reconstitution of the naive B-cell population. J Virol 84: 2466-2476.
62. Malaspina A, Moir S, Kottilil S, Hallahan CW, Ehler LA, et al. (2003) Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol 170: 5965-5972.
63. Calame KL, (2001) Plasma cells: finding new light at the end of B cell development. Nat Immunol 2: 1103-1108.
64. Beniguel L, Begaud E, Cognasse F, Gabrie P, Mbolidi CD, et al. (2004) Specific antibody production by blood B cells is retained in late stage drug-naive HIV-infected Africans. Clin Dev Immunol 11: 121-127.
65. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, et al. (2006) Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 80: 5211-5218.
66. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, et al. (2007) Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 81: 6187-6196.
67. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, et al. (2008) Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82: 11651-11668.
68. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, et al. (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83: 7337-7348.
69. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 7: e1001251.
70. Blish CA, Jalalian-Lechak Z, Rainwater S, Nguyen MA, Dogan OC, et al. (2009) Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J Virol 83: 7783-7788.
71. Cecilia D, Kleeberger C, Munoz A, Giorgi JV, Zolla-Pazner S, (1999) A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis 179: 1365-1374.
72. Zhang YJ, Fracasso C, Fiore JR, Bjorndal A, Angarano G, et al. (1997) Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis 176: 1180-1187.
73. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, et al. (1997) Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 176: 924-932.
74. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232-13252.
75. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, et al. (1999) Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 179: 68-73.
76. Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, et al. (2006) Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 42: 843-852.
77. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, et al. (2008) Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 197: 707-713.
78. Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, et al. (2009) Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 83: 791-801.
79. Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, et al. (2010) Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 84: 7161-7173.
80. Chung A, Rollman E, Johansson S, Kent SJ, Stratov I, (2008) The utility of ADCC responses in HIV infection. Curr HIV Res 6: 515-519.
81. Koup RA, Robinson JE, Nguyen QV, Pikora CA, Blais B, et al. (1991) Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS 5: 1309-1314.
82. Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW, (2001) Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 75: 12161-12168.
83. Eller MA, Eller LA, Ouma BJ, Thelian D, Gonzalez VD, et al. (2009) Elevated natural killer cell activity despite altered functional and phenotypic profile in Ugandans with HIV-1 clade A or clade D infection. J Acquir Immune Defic Syndr 51: 380-389.